Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery
Latest Information Update: 05 Oct 2023
At a glance
- Drugs SGM 101 (Primary)
- Indications Rectal cancer
- Focus Diagnostic use
- Acronyms SGM-LARRC
Most Recent Events
- 05 Oct 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently(Last verified Nov 2020).
- 06 Sep 2019 New trial record